Co-administration of CG250 and IL-2 or IFN-alpha to treat cancer such as renal cell carcinomas

摘要

An anti-tumor antibody directed against the MN (G250) antigen in combination with IFN-! low dose to treat renal cell carninoma, in which the IFN-! Low dose is for administration in a first stage of treatment, and in which the antitumor antibody and IFN-! Low dose are for co-administration in a second stage of treatment, and in which the dose of IFN-! It is in the range of 1-10 MIU three times a week.